Mesothelin-Targeted Immunotherapy Pipeline Market Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24 oct. 2024 10h15 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Mesothelin-Targeted Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic...
IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24 oct. 2024 10h10 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic...
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences
24 oct. 2024 08h30 HE
|
Calidi Biotherapeutics, Inc
- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic diseases,...
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
23 oct. 2024 08h31 HE
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
EvolveImmune Therapeutics to Present New Preclinical Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
23 oct. 2024 07h00 HE
|
EvolveImmune
Multiple Presentations on Lead Development Candidate EVOLVE104 to Showcase Preclinical Safety and Efficacy Profile and Precision Therapeutic Strategy as Company Advances Program Toward Clinic for...
Checkpoint Inhibitor Refractory Cancer (PD-L1 and PD-1) Market Research Report 2024-2030: Biomarker Testing Revolutionizes Treatment, Personalized Medicine and Immunotherapy Bolster Growth
23 oct. 2024 06h33 HE
|
Research and Markets
Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "Global Checkpoint Inhibitor Refractory Cancer Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Application, End-User,...
Food Allergy Market Report 2024: $40+ Billion Industry to Grow at a CAGR of 6.7% During 2025-2030 - Innovations in Immunotherapy allergology Open New Avenues in Treatment
22 oct. 2024 09h00 HE
|
Research and Markets
Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Food Allergy Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Allergen Source, Treatment Type, Channel, Region, By...
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
17 oct. 2024 08h07 HE
|
BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
Immunology Collaboration and Licensing Agreements Trends Report 2024: Explore 862 Detailed Contract Documents via SEC Submissions - Access Deal Payment Terms and Trigger Clauses
14 oct. 2024 06h46 HE
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
11 oct. 2024 06h00 HE
|
Turnstone Biologics Corp.
Turnstone Biologics announces strategic restructuring to prioritize portfolio and extend financial runway.